To implement a similar strategy in humans, DC vaccines were prepared from autologous immunomagnetically isolated CD14+ monocytes in 7-day differentiation cultures with GM-CSF and IL-4, loaded with freeze/thaw tumor lysates from a needle tumor biopsy, and matured for 24 h with Hiltonol, IFN-a and TNF-a. Identity, purity and maturation of the DC products were as shown in supplementary Figure S2, available at Annals of Oncology online and consistent with our previously reported trials of similar cell therapy products [21, 22].
That is clearly an ATL-DC with Poly-ICLC added in to the final activation stage.